$LIFE

Kucharski Brandt Walter sold $2.9M of LIFE

Kucharski Brandt Walter (Chief Accounting Officer) sold 83,047 shares of Ethos Technologies Inc. (LIFE) at an average of $34.88 ($34.18–$35.44, $2.90M total) across 4 trades over 2026-08-14 to 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kucharski Brandt Walter
Published Aug 18, 2026, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 10:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LIFE
Neutral
medium confidence
Mentioned
$LIFE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LIFENeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price range, and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the $2.9M sale, but there is no accompanying guidance, earnings, or regulatory development in the text.

03

What to watch

10b5-1 plans are often scheduled regardless of fundamentals; without additional context (e.g., other insiders selling, earnings timing), the signal is weak.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-18 after-hours

Background

The article is an SEC Form 4 insider transaction disclosure for Ethos Technologies Inc. (LIFE).

Company-level read

Ticker impact

$LIFENeutralMedium confidence
Context

Ethos Technologies CFO Kucharski Brandt Walter sold about $2.9M of LIFE shares via an open-market sale under a 10b5-1 plan.

Expected impact

Likely limited, short-lived impact unless follow-on selling or other disclosures emerge.

Evidence & confidence

Form 4 shows a pre-arranged 10b5-1 sale of common stock by an accounting officer; the filing provides transaction details but no new operating or financial information.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

A large, multi-tranche sale can still be interpreted by some traders as management reducing exposure, even if 10b5-1 is pre-arranged.

Key entities

  • Ethos Technologies Inc.

    Company whose insider transaction was disclosed on Form 4.

  • Kucharski Brandt Walter

    Chief Accounting Officer who sold shares.

  • 10b5-1 plan

    Pre-arranged plan that can reduce the interpretive value of insider-sale timing.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LIFEMed

JPMorgan downgrades Ethos Technologies stock rating to neutral

JPMorgan downgraded Ethos Technologies (LIFE) to Neutral from Overweight, setting a $37 price target. The stock has surged 99% year-to-date. JPMorgan notes growth potential but cites balanced risk-reward and relative valuation concerns. Ethos reported Q2 2026 revenue of $189.6M, up 113% YoY, and raised full-year guidance to $727M-$731M. Other firms adjusted targets post-results.

$LIFEMed

Ethos (LIFE) Grows Revenue 113% While Margins Quietly Compress

Ethos Technologies (LIFE) reported Q2 revenue growth of 113% to $189.6M, with new policies up 133%. Gross profit margin was 98%, but net income rose only 5% to $19.5M. The company authorized a $100M stock buyback. Q3 revenue guidance is $160M-$164M, and full-year guidance is $727M-$731M. Margins compressed, with GAAP net loss of $146.9M for H1 2026 due to stock-based compensation.

$LIFEMedAI 9/10

Ethos (LIFE) Q2 2026 Earnings Call Transcript

Ethos Technologies (LIFE) reported Q2 2026 revenue of $189.6 million, up 113% Y/Y, with direct revenue $116.5 million (+131%) and third-party revenue $73.1 million (+90%). Adjusted EBITDA was $35.2 million (19% margin). Net income was $19.5 million. Full-year 2026 guidance: revenue $727-$731 million and adjusted EBITDA $119-$123 million. Up to $100 million Class A repurchase authorized.

$LIFEMed

Top SMid Cap Pick: Ethos Technologies Leads Citi’s Rankings

Citi analyst Ronald Josey named Ethos Technologies (LIFE) his top SMID-cap pick after the company’s Q2 results. Activated policies growth accelerated to 133% YoY, with 107,800 net activated policies. Revenue rose to $189.6M (+113% YoY). Ethos raised 2026 revenue guidance to $727M-$731M and adjusted EBITDA to $119M-$123M. Citi lifted its price target to $33 and kept Buy/High Risk.